Skip to main content
Louis J. Aronne on Muck Rack

Louis J. Aronne

New York
As seen in: Color Research & Application, Nature, Wiley Online Library, U.S. News and World Report, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Medscape, The New England Journal of Medicine, Women's Health, The Lancet and
Louis J. Aronne, MD, FACP, DABOM Director, Comprehensive Weight Control Center Weill Cornell Medicine Past Chairman, American Board of Obesity Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Louis J.

Contact Louis J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Relationship of Early Rapid Weight Loss to Efficacy and Safety of Tirzepatide and Semaglutide for Obesity: Surmount-5 Post Hoc Analysis

|
By Louis J. Aronne
| Texas Medical Center
Faculty, Staff and Student Publications Publication Date 7-1-2026 Journal The American Journal of Medicine DOI 10.1016/j.amjmed.2026.03.010 Abstract Background: A knowledge gap remains in how the rate of body weight reduction impacts efficacy and safety of obesity management medications. This SURMOUNT-5 post hoc analysis aimed to define rapid responders and evaluated efficacy and safety of tirzepatide versus. semaglutide in rapid responders versus non-rapid responders.
Open in Who Shared Issue with article?

American Diabetes Association Scientific Sessions

|
By Katie Kalvaitis Verified, RICHARD SMITH, Louis J. Aronne
| Citeline Verified
Key takeaways: Berobenatide is an ultralong-acting GLP-1 receptor agonist. Phase 2b data show berobenatide conferred robust weight loss and tolerability across different doses and intervals. Phase 3 program is underway. NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or overweight, with and without type 2 diabetes.
Open in Who Shared Issue with article?

American Diabetes Association Scientific Sessions

|
By Katie Kalvaitis Verified, RICHARD SMITH, Louis J. Aronne
| Citeline Verified
Key takeaways: Berobenatide is an ultralong-acting GLP-1 receptor agonist. Phase 2b data show berobenatide conferred robust weight loss and tolerability across different doses and intervals. Phase 3 program is underway. NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or overweight, with and without type 2 diabetes.
Open in Who Shared Issue with article?
See all 35 licensed articles (38 Total)